Author

Daniel Olson

Observed name: D. Olson

Institutions: University of Chicago, University of Chicago Medicine Comprehensive Cancer Center

Observed institutions: University of Chicago, University of Chicago Medicine Comprehensive Cancer Center

ORCID: 0000-0001-8902-7661

Observed ORCID: 0000-0001-8902-7661

OpenAlex ID: A5132858478

Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology

2026 · Susan M. Swetter, Douglas Johnson, et al. · Journal of the National Comprehensive Cancer Network · 4

Phase 1A/B study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab, in patients with advanced solid tumor malignancies.

2026 · Harriet M. Kluger, Alain Patrick Algazi, et al. · Journal of Clinical Oncology · 1

Abstract 5392: Targeting solid tumors with pH-dependent dual-specific TCEs: First-in-human development of CT-202

2026 · Stanley Roberts, Kelly Byrnes-Blake, et al. · Cancer Research · 1

Stepping on the Gas or Hitting the Brakes: Response-Driven Therapy for Melanoma

2026 · Afsaneh Amouzegar, Reid Shaw, et al. · American Society of Clinical Oncology Educational Book

Clinical and translational results from the phase 1 portion of the phase 1/2 study to evaluate CHM-2101, an autologous cadherin 17 (CDH17) chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed or refractory gastrointestinal cancers.

2026 · Jennifer Rachel Eads, Daniel Olson, et al. · Journal of Clinical Oncology

Autologous T-cell antigen coupler targeting HER2 (TAC01-HER2) in advanced or metastatic solid tumors

2026 · E.E. Dumbrava, D. Olson, et al. · Annals of Oncology

Works count: 6

Citation count: 5

H-index: 1

I10-index: